TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients. TS-1 inhibits DNA replication, a process that is crucial for cell proliferation and tumor growth. Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is an irreversible inhibitor of thymidylate synthase, an enzyme that is essential for DNA replication. Gimeracil enhances the anti-tumor effects of 5-FU by preventing its degradation within cells. Oteracil potassium reduces the serious gastrointestinal (GI) toxicity caused by 5-FU by inhibiting the phosphorylation of 5-FU in the GI tract.
4 Drug Overview
5 Product Profiles
5 TS-1 : Colorectal cancer (CRC)
LIST OF FIGURES
8 Figure 1: TS-1 for colorectal cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of TS-1 in colorectal cancer
12 Figure 4: TS-1 sales for colorectal cancer in Japan, 2016–25
LIST OF TABLES
5 Table 1: TS-1 drug profile
7 Table 2: TS-1 pivotal trial data in colorectal cancer
12 Table 3: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
13 Table 4: Patients treated with TS-1 in Japan, 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.